US-CT Fusion for Post Implant Dosimetry

Comparison Between Postoperative Ultrasound-CT Fusion With MRI-CT Fusion for Postimplant Dosimetry for Prostate LDR Permanent Seed Brachytherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03692104

Enrollment

Registered

2018-10-02

Start date

2017-11-03

Completion date

2019-12-31

Last updated

2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate cancer, brachytherapy, Quality assurance

Brief summary

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

Detailed description

25 participants undergoing permanent seed prostate brachytherapy will be approached to undergo collection of prostate US images at the completion of their procedure. This will add approximately 5 minutes to the duration of their brachytherapy procedure. The US study will not entail any discomfort or risk to participants as they are still under anesthesia for the implant procedure. The institution standard of care for quality assurance will be complied with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be co-registered and analyzed in the normal fashion. In addition, the post implant US images will also be co-registered with the CT and the resulting dosimetric parameters compared.

Interventions

DIAGNOSTIC_TESTtransrectal ultrasound

Use of US for post implant quality assessment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* localized prostate cancer suitable for permanent seed implant brachytherapy as either monotherapy or as a boost

Exclusion criteria

* Unable to undergo MRI

Design outcomes

Primary

Measure	Time frame	Description
Comparison of prostate dosimetry assessed by US-CT fusion with respect to the standard MR-CT fusion	1 month	Dosimetry will be calculated using 2 different imaging modalities (US vs MRI) and compared

Secondary

Measure	Time frame	Description
Comparison of prostate volume assessed by 2 different imaging modalities	1 month	Assessment of prostate volume as contoured on US vs MRI post implant

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026